8-K: Phio Pharmaceuticals Secures $3.1 Million Through Warrant Exercises

Phio Pharmaceuticals has successfully raised approximately $3.1 million by inducing warrant holders to exercise their existing warrants at a reduced price, while issuing new warrants.

Summary

• Phio Pharmaceuticals Corp. entered into agreements with existing warrant holders to exercise their warrants at a reduced price of $5.45 per share.
• The company issued new unregistered Series C and Series D warrants in exchange for the exercise of the existing warrants and an additional payment of $0.125 per new warrant.
• The Series C warrants are exercisable for 583,098 shares with a term of five and a half years, while the Series D warrants are exercisable for 507,474 shares with a term of eighteen months.
• The gross proceeds from the exercise of the warrants are expected to be approximately $3.1 million before deducting fees and expenses.
• H.C. Wainwright & Co. acted as the exclusive placement agent for this transaction.
• The company intends to use the net proceeds for working capital and other general corporate purposes.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the company has successfully raised capital, but there are some risks and restrictions associated with the new warrants.

Positives

• The company successfully raised $3.1 million in gross proceeds.
• The warrant exercise provides immediate capital to the company.
• The new warrants have the potential to bring in additional capital if exercised.
• The company has secured a commitment to file a registration statement for the resale of the new warrant shares.

Negatives

• The new warrants are unregistered, which may limit their immediate tradability.
• The company is subject to a 90-day lock-up period on issuing new shares or equivalents, with a potential early release if the stock price exceeds $6.50 for five consecutive trading days after 30 days.
• The company will incur placement agent fees and offering expenses, reducing the net proceeds.

Risks

• The new warrants are subject to beneficial ownership limitations, which may affect their exercise.
• The company may face challenges in maintaining the effectiveness of the resale registration statement.
• Failure to deliver warrant shares on time could result in penalties for the company.
• The company is subject to potential buy-in costs if it fails to deliver shares on time.
• The company is subject to potential liquidated damages if the resale registration statement is not filed or declared effective by certain dates.

Future Outlook

The company intends to use the net proceeds from the offering for working capital and other general corporate purposes and will file a registration statement for the resale of the new warrant shares.

Management Comments

• Phio Pharmaceuticals is pleased to offer to you the opportunity to exercise all of the warrants to purchase shares of the Companys common stock.
• The company intends to use the net proceeds from the offering for working capital and other general corporate purposes.

Industry Context

This transaction is a common method for biotechnology companies to raise capital, especially those in the clinical stage. The use of warrants and private placements is a typical approach to secure funding while minimizing immediate dilution.

Comparison to Industry Standards

• The use of inducement warrants to encourage the exercise of existing warrants is a common practice in the biotech industry.
• The terms of the new warrants, including the exercise price and term, are within the typical range for similar transactions.
• The placement agent fees and expenses are also within the industry standard for such offerings.
• The lock-up period and resale registration requirements are standard for private placements of this nature.
• Comparable companies often use similar methods to raise capital, such as private placements, follow-on offerings, and warrant exercises.

Stakeholder Impact

• Shareholders may experience dilution if the new warrants are exercised.
• The company's financial position is strengthened by the capital raise.
• The company's ability to fund operations and research is improved.
• The company's stock price may be affected by the offering and the potential for future dilution.

Next Steps

• The company will file a registration statement for the resale of the new warrant shares.
• The company will use the net proceeds for working capital and other general corporate purposes.
• The company will monitor the stock price to determine if the lock-up period can be lifted early.

Key Dates

Keywords

warrants, common stock, exercise, private placement, registration statement, placement agent, inducement, capital raise, biotechnology, immuno-oncology